SURMOUNT-1 Tirzepatide The pivotal tirzepatide trial, published in the New England Journal of Medicine in 2022, randomized 2,539 adults with obesity to tirzepatide 5 mg, 10 mg, 15 mg or placebo for 72 weeks
Toll-like Receptor 4: A promising therapeutic target for Alzheimers disease
doi: 10.3389/fnins.2025.1671955 Received 24 July 2025 Revised 10 December 2025 Accepted 16 December 2025 Published 13 January 2026 Volume 19 - 2025 Edited by Fangchen Gong, Shanghai Jiao Tong University, China Reviewed by Al-Shaimaa Faissal Ahmed, Minia University, Egypt John Sieh Dumbuya, Affiliated Hospital of Guangdong Medical University, China Updates Copyright 2026 Li, Wang, Ma, Peng, Wang, Wang, Li and Wang
nevertheless, acetaminophen toxicity is the leading cause of acute liver failure in the United States
This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal (eg, St
However, it also has an important role in the digestive system, immune system, and cognitive functioning